Dr. Michael Johnson

    Treatment of Macular Hole

    8/14/2018 12:00:00 AM

  • Treatment of Macular Hole 08/14/2018

    Healthy Living – August 14, 2018
    Michael Johnson, MD – Eastern Maine Medical Center
     Johnson.jpg
    The inverted internal limiting membrane (ILM) flap technique, first described by Michalewska et al in 2010, is an effective surgical technique for treating large idiopathic full thickness macular holes (MHs) and myopic MHs.1 These authors reported that the innovative technique increased their rate of complete MH closure to 98% for large idiopathic MHs (diameter exceeding 400 mm), compared with an 88% closure rate with conventional vitrectomy and ILM peeling. This excellent anatomic result was associated with significant functional improvement in visual acuity, and the postoperative flat, open appearance of MHs was not observed.

    The Technique and Science
     In the inverted ILM flap technique, after core vitrectomy and dye staining, the ILM is not completely removed from the retina but is left in place, attached to the edges of the MH. This ILM remnant is then inverted to cover and fill the MH. Finally, fluid-air exchange is performed.
     
    Several mechanisms have been proposed to explain the tissue repair that occurs following use of the inverted ILM flap technique. The inverted ILM, containing Müller cell fragments, may induce glial cell proliferation, filling the MH and supporting MH closure. It may also work as a scaffold for tissue proliferation, creating a microenvironment that encourages correct photoreceptor positioning and finally improving postoperative anatomic and functional outcome. This hypothesis is in agreement with histopathologic findings suggesting that a basement membrane is required for cell proliferation. Because ILM is a basement membrane, it allows glial cell proliferation, and large MHs fill with tissue over time.

    Early Experience
     Many authors have since reported similar satisfactory results with the inverted flap technique for treating large idiopatic MHs, further expanding its use to myopic MH and repeat MH surgery.2,3 Michalewska et al also confirmed similar encouraging results in the treatment of myopic MH without retinal detachment.4 They reported that the rate of complete closure was 100% for high-myopic MHs, and they confirmed that the process of foveal architectural repair after the surgery continued over at least a 12-month period. This technique allowed not only a high closure rate in myopic MHs, but also a functional improvement in visual acuity. A recent study compared the results of vitrectomy plus complete ILM removal with the results of the inverted ILM flap technique in the treatment of myopic MH without retinal detachment.5 The functional and anatomic outcomes reported with the inverted ILM flap technique were superior to those with complete ILM to ILM removal for myopic MH with retinal detachment.6 They reported anatomic and functional improvement when the inverted ILM flap was inserted into the myopic MH. The use of an inverted ILM flap over the MH seems to be more effective than complete ILM peeling in these challenging cases. Variants of the classic inverted flap technique have been described, including autologous extramacular retinal free flap autotransplantation for reoperation cases in which there is no ILM bordering the MH.7 To minimize iatrogenic trauma associated with ILM peeling, Michalewska et al introduced a modified procedure in which ILM is peeled from the temporal side of the fovea only. They found that this temporal inverted ILM flap technique was as effective as the classic inverted ILM flap technique for the repair of large MHs.8
     
    Personal Experience
     In our own experience, the inverted ILM flap technique appears to be a safe and successful procedure for the management of large idiopathic MHs and myopic MHs. We have treated patients with idiopathic large MHs (diameter >400 mm) and with large myopic MHs (diameter >400 mm) using pars plana vitrectomy and the inverted ILM flap technique. Swept-source optical coherence tomography (OCT), spectral-domain OCT, OCT angiography, and adaptive optics images were used to assess the anatomic outcomes of surgery, and BCVA and microperimetry were used to evaluate the functional outcomes during 6 months of follow-up. MH closure was observed in 97.5% of patients after one procedure. On OCT images, the healing process showed the appearance of a hyperreflective material filling the MH; gradually, this material contracted, inducing MH closure. All patients showed improvement in visual function, both removal for the treatment of myopic MH. Other authors have compared the inverted flap technique in BCVA and multifocal electroretinography responses, during the first 3 months after surgery. We observed different OCT findings after the classic ILM flap technique and ILM autotransplantation: In the former, we could see restoration of normal foveal architecture during follow-up (Figure 1); in the latter, we observed the persistence of a glial plug during follow-up (Figure 2). We have hypothesized that there are two different mechanisms of MH closure with the two techniques. After the classic inverted flap technique, the ILM acts like a scaffold for tissue proliferation, producing an environment for the photoreceptors to assume new positions in direct proximity to the fovea, and perfect anatomic restoration takes place. After ILM autotransplant, by contrast, the glial plug remains visible during follow-up.
     
    Conclusion
    Vitrectomy with the inverted ILM flap technique seems to be a safe and effective surgery for idiopathic and myopic large MHs, improving both functional and anatomic outcomes. Postoperative evaluation with new retinal imaging techniques including structural OCT, OCT angiography, and adaptive optics, and with functional tests such as microperimetry, may help to elucidate the structural and functional changes associated with this surgical technique and to understand the mechanisms of postoperative improvement observed in the retinal architecture. 

    Read More

  • Cellular Regeneration Strategies for Macular Degeneration 07/10/2018

    Cellular Regeneration Strategies for Macular Degeneration

    Read More

  • Geographic Atrophy Now in Researchers’ Sights 06/12/2018

    Geographic Atrophy Now in Researchers’ Sights

    Read More

  • FDA Approves Gene Therapy to Treat Patients with Rare Form of Inherited Vision Loss 05/22/2018

    FDA Approves Gene Therapy to Treat Patients with Rare Form of Inherited Vision Loss

    Read More

  • Screening for Diabetic Retinopathy 04/24/2018

    Read More

  • How Will Diabetic Retinopathy Clinical Research Network Protocol S Change Our Practice? 01/09/2018

    Read More

  • New FDA Approved Drug for Eye Swelling 12/12/2017

    New FDA Approved Drug for Eye  Swelling

    Read More

  • Surgical Management of Sub Retinal Hemorrhage 10/24/2017

    Surgical Management of Sub Retinal Hemorrhage 

    Read More

  • New Treatment for Diabetic Retinopathy 09/19/2017

    New Treatment for Diabetic Retinopathy

    Read More

  • Endophthalmitis 08/22/2017

    Endophthalmitis

    Read More

  • Retinal Pigment Epithelial Transplant Geographic Atrophy 05/23/2017

    For years, people were throwing away cells that could bring eyesight to the blind. These dark, blackened cells looked like spots of contamination in the petri dishes in which researchers around the world were carefully nurturing highly purified colonies of human stem cells.

    Read More

  • Retinal Prosthesis 04/25/2017

    Retinal Prosthesis

    Read More

  • Central Serous Retinopathy 01/24/2017

    Central Serous Retinopathy

    Read More

  • Retinal Vein Occlusion 11/15/2016

    Retinal Vein Occlusion

    Read More

  • Optogenetics

    Optogenetics

    Read More